Cargando…

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis

BACKGROUND: Neuropilin (NRP) is a transmembrane protein, which has been shown to be a pro-angiogenic mediator and implicated as a potential driver of cancer progression. NRP-1 up-regulation in ovarian cancer tissue predicts poor prognosis. However, the clinical relevance of the soluble form of NRP-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klotz, Daniel Martin, Kuhlmann, Jan Dominik, Link, Theresa, Goeckenjan, Maren, Hofbauer, Lorenz C., Göbel, Andy, Rachner, Tilman D., Wimberger, Pauline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635484/ https://www.ncbi.nlm.nih.gov/pubmed/36338759 http://dx.doi.org/10.3389/fonc.2022.974885

Ejemplares similares

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2021)

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
por: Göbel, Andy, et al.
Publicado: (2020)

Diagnostic Benefit of the Detection of Mitotic Figures in Endometriotic Lesions
por: Wetzk, Michelle, et al.
Publicado: (2022)

Correction: Diagnostic Benefit of the Detection of Mitotic Figures in Endometriotic Lesions
por: Wetzk, Michelle, et al.
Publicado: (2023)

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
por: Göbel, Andy, et al.
Publicado: (2019)

Continuous Body Temperature Monitoring to Improve the Diagnosis of Female Infertility
por: Goeckenjan, Maren, et al.
Publicado: (2020)

Correction: Continuous Body Temperature Monitoring to Improve the Diagnosis of Female Infertility
por: Goeckenjan, Maren, et al.
Publicado: (2023)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013)

Met and its ligand HGF are associated with clinical outcome in breast cancer
por: Veenstra, Cynthia, et al.
Publicado: (2016)

Regulation of VEGF by mevalonate pathway inhibition in breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2013)

The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
por: Göbel, Andy, et al.
Publicado: (2021)

Prospects of adjuvant RANKL inhibition in breast cancer?
por: Rachner, T D, et al.
Publicado: (2015)

Fatal attraction: why breast cancer cells home to bone
por: Hofbauer, Lorenz C, et al.
Publicado: (2008)

From bone to breast and back - the bone cytokine RANKL and breast cancer
por: Hofbauer, Lorenz C, et al.
Publicado: (2011)

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies
por: Todenhöfer, Tilman, et al.
Publicado: (2015)

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
por: Wilke, Maria, et al.
Publicado: (2014)

HGF-MET as a breast cancer biomarker
por: Liu, Shuying
Publicado: (2015)

HGF/c-MET Signaling in Melanocytes and Melanoma
por: Czyz, Malgorzata
Publicado: (2018)

HGF–Met Pathway in Regeneration and Drug Discovery
por: Matsumoto, Kunio, et al.
Publicado: (2014)

HGF/Met Axis in Heart Function and Cardioprotection
por: Gallo, Simona, et al.
Publicado: (2014)

Physiological Signaling and Structure of the HGF Receptor MET
por: Baldanzi, Gianluca, et al.
Publicado: (2014)

HGF/MET Signaling in Malignant Brain Tumors
por: Mulcahy, Elizabeth Qian Xu, et al.
Publicado: (2020)

Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity
por: Bemmerlein, Lila, et al.
Publicado: (2022)

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
por: Browne, Andrew J., et al.
Publicado: (2017)

Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
por: Link, Theresa, et al.
Publicado: (2019)

The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro
por: Schott, Sarah, et al.
Publicado: (2017)

Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
por: Cao, Hui-Hui, et al.
Publicado: (2015)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

The role of HGF/c-MET signaling pathway in lymphoma
por: Lam, Bao Quoc, et al.
Publicado: (2016)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
por: Cruickshanks, Nichola, et al.
Publicado: (2017)

Cyclic Peptide-Based Biologics Regulating HGF-MET
por: Sato, Hiroki, et al.
Publicado: (2020)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
por: Wang, Haiyu, et al.
Publicado: (2020)

Targeting HGF/c-MET Axis in Pancreatic Cancer
por: Pothula, Srinivasa P., et al.
Publicado: (2020)

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma
por: Tanaka, Ryota, et al.
Publicado: (2021)

HGF and MET: From Brain Development to Neurological Disorders
por: Desole, Claudia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jfdpevb750797hceoalu4vioc5